Search Results for: JUN

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
NCOA6 nuclear receptor coactivator 6
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional regulation of white adipocyte differentiation
  • Regulation of lipid metabolism by PPARalpha
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Cytoprotection by HMOX1
  • Heme signaling
  • Formation of WDR5-containing histone-modifying complexes
  • Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
NCOR2 nuclear receptor corepressor 2
  • PPARA activates gene expression
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • HDACs deacetylate histones
  • Notch-HLH transcription pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Loss of MECP2 binding ability to the NCoR/SMRT complex
  • Regulation of MECP2 expression and activity
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • HCMV Early Events
  • NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis
  • Cytoprotection by HMOX1
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
NEDD4 NEDD4 E3 ubiquitin protein ligase
  • ISG15 antiviral mechanism
  • Downregulation of ERBB4 signaling
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Antigen processing: Ubiquitination & Proteasome degradation
NELFB negative elongation factor complex member B
  • Formation of RNA Pol II elongation complex
  • Formation of the Early Elongation Complex
  • Formation of HIV elongation complex in the absence of HIV Tat
  • Formation of the HIV-1 Early Elongation Complex
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Formation of HIV-1 elongation complex containing HIV-1 Tat
  • Pausing and recovery of Tat-mediated HIV elongation
  • Abortive elongation of HIV-1 transcript in the absence of Tat
  • Tat-mediated HIV elongation arrest and recovery
  • Tat-mediated elongation of the HIV-1 transcript
  • HIV elongation arrest and recovery
  • Pausing and recovery of HIV elongation
  • RNA Polymerase II Pre-transcription Events
  • TP53 Regulates Transcription of DNA Repair Genes
  • RNA Polymerase II Transcription Elongation
  • NTRK3 as a dependence receptor
NFE2L1 NFE2 like bZIP transcription factor 1
  • Dodecyldimethylamine N-oxide
NFE2L2 NFE2 like bZIP transcription factor 2
  • Neddylation
  • Potential therapeutics for SARS
  • Regulation of HMOX1 expression and activity
  • Heme signaling
  • KEAP1-NFE2L2 pathway
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • NFE2L2 regulating TCA cycle genes
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
NFYA nuclear transcription factor Y subunit alpha
  • PPARA activates gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Activation of gene expression by SREBF (SREBP)
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • ATF6 (ATF6-alpha) activates chaperone genes
  • ATF6 (ATF6-alpha) activates chaperone genes
  • FOXO-mediated transcription of cell death genes
NFYC nuclear transcription factor Y subunit gamma
  • PPARA activates gene expression
  • Activation of gene expression by SREBF (SREBP)
  • Activation of gene expression by SREBF (SREBP)
  • ATF4 activates genes in response to endoplasmic reticulum stress
  • ATF6 (ATF6-alpha) activates chaperone genes
  • ATF6 (ATF6-alpha) activates chaperone genes
  • FOXO-mediated transcription of cell death genes
NR3C1 nuclear receptor subfamily 3 group C member 1
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • SUMOylation of intracellular receptors
  • PTK6 Expression
  • Regulation of RUNX2 expression and activity
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Potential therapeutics for SARS
  • Regulation of NPAS4 gene transcription
  • Flunisolide
  • Diflorasone
  • Alclometasone
  • Medrysone
  • Amcinonide
  • Fluorometholone
  • Megestrol acetate
  • Levonorgestrel
  • Beclomethasone dipropionate
  • Progesterone
  • Spironolactone
  • Betamethasone
  • Desoximetasone
  • Fluticasone propionate
  • Fluocinolone acetonide
  • Ulobetasol
  • Triamcinolone
  • Prednisone
  • Flumethasone
  • Fludrocortisone
  • Norethisterone
  • Hydrocortisone
  • Mometasone
  • Hydrocortamate
  • Mifepristone
  • Clocortolone
  • Flurandrenolide
  • Prednisolone
  • Loteprednol etabonate
  • Rimexolone
  • Methylprednisolone
  • Clobetasol propionate
  • Fluocinonide
  • Prednicarbate
  • Fluoxymesterone
  • Budesonide
  • Dexamethasone
  • Desonide
  • Cortisone acetate
  • Paramethasone
  • Drospirenone
  • Ciclesonide
  • Hexane-1,6-Diol
  • Aldosterone
  • ORG-34517
  • Difluprednate
  • Ulipristal
  • Fluticasone furoate
  • Tixocortol
  • Difluocortolone
  • Gestrinone
  • Deflazacort
  • Onapristone
  • Cortivazol
  • Clobetasone
  • Fluticasone
  • Mometasone furoate
  • Hydrocortisone aceponate
  • Hydrocortisone acetate
  • Hydrocortisone butyrate
  • Hydrocortisone cypionate
  • Hydrocortisone phosphate
  • Hydrocortisone probutate
  • Hydrocortisone valerate
  • Segesterone acetate
  • Prednisolone phosphate
  • Dexamethasone acetate
  • Betamethasone phosphate
  • Prednisolone acetate
  • 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
NR5A1 nuclear receptor subfamily 5 group A member 1
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Transcriptional regulation of pluripotent stem cells
  • Transcriptional regulation of testis differentiation
  • (2R)-3-{[{[(2S)-2,3-DIHYDROXYPROPYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-[(9E)-HEXADEC-9-ENOYLOXY]PROPYL (9E)-OCTADEC-9-ENOATE
  • Phosphatidyl ethanol
  • Premature ovarian failure
  • 46,XY disorders of sex development (Disorders of gonadal development), including: Gonadal agenesis; Complete and partial gonadal dysgenesis; Testis regression; Ovotesticular DSD
NRIP1 nuclear receptor interacting protein 1
  • SUMOylation of transcription cofactors
  • Estrogen-dependent gene expression
  • NR1H2 & NR1H3 regulate gene expression linked to lipogenesis
  • NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis
  • Heme signaling
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
  • 4-HYDROXY-N'-(4-ISOPROPYLBENZYL)BENZOHYDRAZIDE
NTRK3 neurotrophic receptor tyrosine kinase 3
  • PIP3 activates AKT signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Receptor-type tyrosine-protein phosphatases
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • NTF3 activates NTRK3 signaling
  • NTF3 activates NTRK3 signaling
  • Signaling by NTRK3 (TRKC)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through RAS
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • NTRK3 as a dependence receptor
  • Entrectinib
  • Fostamatinib
  • Larotrectinib
  • Pralsetinib
  • Neuroblastoma
PACS1 phosphofurin acidic cluster sorting protein 1
  • Nef mediated downregulation of MHC class I complex cell surface expression
PHOX2A paired like homeobox 2A
  • Congenital fibrosis of the extraocular muscles (CFEOM)
PIAS1 protein inhibitor of activated STAT 1
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of transcription factors
  • SUMOylation of ubiquitinylation proteins
  • SUMOylation of transcription cofactors
  • SUMOylation of intracellular receptors
  • SUMOylation of intracellular receptors
  • SUMOylation of chromatin organization proteins
  • Formation of Incision Complex in GG-NER
  • Regulation of IFNG signaling
PIAS2 protein inhibitor of activated STAT 2
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
PIN1 peptidylprolyl cis/trans isomerase, NIMA-interacting 1
  • ISG15 antiviral mechanism
  • RHO GTPases Activate NADPH Oxidases
  • Regulation of TP53 Activity through Phosphorylation
  • PI5P Regulates TP53 Acetylation
  • Negative regulators of DDX58/IFIH1 signaling
  • Beta-(2-Naphthyl)-Alanine
  • 3,6,9,12,15,18-HEXAOXAICOSANE
PML PML nuclear body scaffold
  • SUMOylation of DNA damage response and repair proteins
  • SUMOylation of ubiquitinylation proteins
  • Regulation of TP53 Activity through Acetylation
  • Interferon gamma signaling
  • Regulation of RUNX1 Expression and Activity
  • Regulation of PTEN localization
  • HCMV Early Events
  • Arsenic trioxide
  • Acute myeloid leukemia (AML)
POU1F1 POU class 1 homeobox 1
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
PPARG peroxisome proliferator activated receptor gamma
  • PPARA activates gene expression
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • SUMOylation of intracellular receptors
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • MECP2 regulates transcription factors
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
  • alpha-Linolenic acid
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Valproic acid
  • Indomethacin
  • Rosiglitazone
  • Fenoprofen
  • Nateglinide
  • Clofazimine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Amiodarone
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • Flufenamic acid
  • Resveratrol
  • Phthalic Acid
  • Capric acid
  • Doconexent
  • Oleic Acid
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • Reglitazar
  • Elafibranor
  • AMG-131
  • CLX-0921
  • Muraglitazar
  • Ertiprotafib
  • Ragaglitazar
  • Tesaglitazar
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • 9(S)-HODE
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • Indeglitazar
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • Triclosan
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • Aleglitazar
  • Clinofibrate
  • Cannabidiol
  • Lobeglitazone
  • Ciglitazone
  • Dexibuprofen
  • Omega-3 fatty acids
  • Curcumin
  • Arhalofenate
  • Isoflavone
  • Naveglitazar
  • Fenofibric acid
  • Fish oil
  • Medical Cannabis
  • Nabiximols
  • Darglitazone
  • Curcumin sulfate
  • Thyroid cancer
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Type II diabetes mellitus

Page 16 out of 19 pages